Searched for: in-biosketch:yes
person:heguya01
Uncovering potential 'herbal probiotics' in Juzen-taiho-to through the study of associated bacterial populations
Montenegro, Diego; Kalpana, Kriti; Chrissian, Christine; Sharma, Ashutosh; Takaoka, Anna; Iacovidou, Maria; Soll, Clifford E; Aminova, Olga; Heguy, Adriana; Cohen, Lisa; Shen, Steven; Kawamura, Akira
Juzen-taiho-to (JTT) is an immune-boosting formulation of ten medicinal herbs. It is used clinically in East Asia to boost the human immune functions. The active factors in JTT have not been clarified. But, existing evidence suggests that lipopolysaccharide (LPS)-like factors contribute to the activity. To examine this possibility, JTT was subjected to a series of analyses, including high resolution mass spectrometry, which suggested the presence of structural variants of LPS. This finding opened a possibility that JTT contains immune-boosting bacteria. As the first step to characterize the bacteria in JTT, 16S ribosomal RNA sequencing was carried out for Angelica sinensis (dried root), one of the most potent immunostimulatory herbs in JTT. The sequencing revealed a total of 519 bacteria genera in A. sinensis. The most abundant genus was Rahnella, which is widely distributed in water and plants. The abundance of Rahnella appeared to correlate with the immunostimulatory activity of A. sinensis. In conclusion, the current study provided new pieces of evidence supporting the emerging theory of bacterial contribution in immune-boosting herbs.
PMCID:4297534
PMID: 25547935
ISSN: 0960-894x
CID: 1419902
The Rho GTPase Rnd1 suppresses mammary tumorigenesis and EMT by restraining Ras-MAPK signalling
Okada, Tomoyo; Sinha, Surajit; Esposito, Ilaria; Schiavon, Gaia; Lopez-Lago, Miguel A; Su, Wenjing; Pratilas, Christine A; Abele, Cristina; Hernandez, Jonathan M; Ohara, Masahiro; Okada, Morihito; Viale, Agnes; Heguy, Adriana; Socci, Nicholas D; Sapino, Anna; Seshan, Venkatraman E; Long, Stephen; Inghirami, Giorgio; Rosen, Neal; Giancotti, Filippo G
We identified the Rho GTPase Rnd1 as a candidate metastasis suppressor in basal-like and triple-negative breast cancer through bioinformatics analysis. Depletion of Rnd1 disrupted epithelial adhesion and polarity, induced epithelial-to-mesenchymal transition, and cooperated with deregulated expression of c-Myc or loss of p53 to cause neoplastic conversion. Mechanistic studies revealed that Rnd1 suppresses Ras signalling by activating the GAP domain of Plexin B1, which inhibits Rap1. Rap1 inhibition in turn led to derepression of p120 Ras-GAP, which was able to inhibit Ras. Inactivation of Rnd1 in mammary epithelial cells induced highly undifferentiated and invasive tumours in mice. Conversely, Rnd1 expression inhibited spontaneous and experimental lung colonization in mouse models of metastasis. Genomic studies indicated that gene deletion in combination with epigenetic silencing or, more rarely, point mutation inactivates RND1 in human breast cancer. These results reveal a previously unappreciated mechanism through which Rnd1 restrains activation of Ras-MAPK signalling and breast tumour initiation and progression.
PMCID:4374353
PMID: 25531777
ISSN: 1465-7392
CID: 1416192
Whole exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A and CUL1 in malignant pleural mesothelioma
Guo, Guangwu; Chmielecki, Juliann; Goparaju, Chandra; Heguy, Adriana; Dolgalev, Igor; Carbone, Michele; Seepo, Sara; Meyerson, Matthew; Pass, Harvey I
Malignant pleural mesothelioma (MPM) is an aggressive neoplasm associated with asbestos exposure. Although previous studies based on candidate gene approaches have identified important common somatic mutations in MPM, these studies have focused on small sets of genes and have provided a limited view of the genetic alterations underlying this disease. Here, we performed whole exome sequencing on DNA from 22 MPMs and matched blood samples, and identified 517 somatic mutations across 490 mutated genes. Integrative analysis of mutations and somatic copy number alterations (SCNAs) revealed frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1. Our study presents the first unbiased view of the genomic basis of MPM.
PMID: 25488749
ISSN: 0008-5472
CID: 1393512
Preclinical testing supports combined BET and BRAF inhibition as a promising therapeutic strategy for melanoma. [Meeting Abstract]
Paoluzzi, Luca; Hanniford, Douglas; Sokolova, Elena; Dolgalev, Igor; Heguy, Adriana; Osman, Iman; Darvishian, Farbod; Wang, Jinhua; Bradner, James E.; Hernando, Eva
ISI:000358613204357
ISSN: 0732-183x
CID: 5236602
GENETIC DETERMINANTS OF IPILIMUMAB OUTCOMES FOR ADVANCED MELANOMA [Meeting Abstract]
Kirchhoff, T; Adaniel, C; Rendleman, J; Kern, E; Fleming, N; Polsky, D; Berman, R; Shapiro, R; Shao, Y; Heguy, A; Osman, I; Pavlick, A
ORIGINAL:0013163
ISSN: 1569-8041
CID: 3589082
NON-UNIFORM NOTCH SIGNALING UNDERLIES HETEROGENEITY WITHIN THE GLIOBLASTOMA STEM CELL POPULATION [Meeting Abstract]
Bayin, NSumru; Si, Sheng; Modrek, Aram; Song, Hae-Ri; Zagzag, David; Dung Minh Hoang; Wadghiri, Youssef Z; Dolgalev, Igor; Baysan, Mehmet; Heguy, Adriana; Barcellos-Hoff, Mary Helen; Placantonakis, Dimitris
ISI:000350452200804
ISSN: 1523-5866
CID: 2340682
Genome-Based Risk Prediction for Early Stage Breast Cancer
Adaniel, Christina; Jhaveri, Komal; Heguy, Adriana; Esteva, Francisco J
Tests to better characterize tumor genomic architecture are quickly becoming a standard of care in oncology. For breast cancer, the use of gene expression assays for early stage disease is already common practice. These tests have found a place in risk stratifying the heterogeneous group of stage I-II breast cancers for recurrence, for predicting chemotherapy response, and for predicting breast cancer-related mortality. In the last 5 years, more assays have become available to the practicing oncologist. Given the rapidity with which this field has evolved, it is prudent to review the tests, their indications, and the studies from which they have been validated. We present a comprehensive review of the available gene expression assays for early stage breast cancer. We review data for several individual tests and comparative studies looking at risk prediction and cost-effectiveness.
PMCID:4200995
PMID: 25187476
ISSN: 1083-7159
CID: 1180912
Trial of a 5-day dosing regimen of temozolomide in patients with relapsed small cell lung cancers with assessment of methylguanine-DNA methyltransferase
Zauderer, Marjorie G; Drilon, Alex; Kadota, Kyuichi; Huberman, Kety; Sima, Camelia S; Bergagnini, Isabella; Sumner, Dyana K; Travis, William D; Heguy, Adriana; Ginsberg, Michelle S; Holodny, Andrei I; Riely, Gregory J; Kris, Mark G; Krug, Lee M; Pietanza, M Catherine
OBJECTIVES: Small cell lung cancers (SCLCs) are characterized by aberrantly methylated O6-methyl-guanine-DNA methyltransferase (MGMT). Epigenetic silencing of MGMT is associated with loss of MGMT activity and improved sensitivity to alkylating agents in glioblastomas. We have reported the activity of temozolomide, a non-classical alkylating agent, in patients with relapsed sensitive or refractory SCLCs, given at 75mg/m2/day for 21 of 28 days. However, prolonged myelosuppression was noted. We therefore evaluated a 5-day dosing schedule of temozolomide and examined MGMT as a predictive biomarker for temozolomide treatment in SCLC. MATERIALS AND METHODS: Patients with sensitive or refractory SCLCs and progression after one or two prior chemotherapy regimens received temozolomide 200mg/m2/day for 5 consecutive days in 28-day cycles. The primary endpoint was tolerability. We also assessed MGMT promoter methylation status by PCR and MGMT expression by immunohistochemistry in tumor specimens. RESULTS: Of 25 patients enrolled, 5 experienced grade 3 or 4 toxicity (anemia, thrombocytopenia, neutropenia, and constipation). The partial response rate was 12% [95% CI: 3-31%], with partial responses in 2 refractory patients. We were able to obtain tumor samples for more than half of patients for MGMT testing. CONCLUSION: Temozolomide 200mg/m2/day for 5 days in 28-day cycles is tolerable and active in patients with relapsed SCLCs. No treatment-limiting prolonged cytopenias were observed, making this our preferred schedule for further studies. Acquisition of archived biospecimens is feasible and necessary in order to continue evaluating the role of MGMT as a predictive biomarker in SCLCs.
PMCID:4497567
PMID: 25194640
ISSN: 0169-5002
CID: 1181282
Genetic Variation in DNA Repair Pathways and Risk of Non-Hodgkin's Lymphoma
Rendleman, Justin; Antipin, Yevgeniy; Reva, Boris; Adaniel, Christina; Przybylo, Jennifer A; Dutra-Clarke, Ana; Hansen, Nichole; Heguy, Adriana; Huberman, Kety; Borsu, Laetitia; Paltiel, Ora; Ben-Yehuda, Dina; Brown, Jennifer R; Freedman, Arnold S; Sander, Chris; Zelenetz, Andrew; Klein, Robert J; Shao, Yongzhao; Lacher, Mortimer; Vijai, Joseph; Offit, Kenneth; Kirchhoff, Tomas
Molecular and genetic evidence suggests that DNA repair pathways may contribute to lymphoma susceptibility. Several studies have examined the association of DNA repair genes with lymphoma risk, but the findings from these reports have been inconsistent. Here we provide the results of a focused analysis of genetic variation in DNA repair genes and their association with the risk of non-Hodgkin's lymphoma (NHL). With a population of 1,297 NHL cases and 1,946 controls, we have performed a two-stage case/control association analysis of 446 single nucleotide polymorphisms (SNPs) tagging the genetic variation in 81 DNA repair genes. We found the most significant association with NHL risk in the ATM locus for rs227060 (OR = 1.27, 95% CI: 1.13-1.43, p = 6.77x10-5), which remained significant after adjustment for multiple testing. In a subtype-specific analysis, associations were also observed for the ATM locus among both diffuse large B-cell lymphomas (DLBCL) and small lymphocytic lymphomas (SLL), however there was no association observed among follicular lymphomas (FL). In addition, our study provides suggestive evidence of an interaction between SNPs in MRE11A and NBS1 associated with NHL risk (OR = 0.51, 95% CI: 0.34-0.77, p = 0.0002). Finally, an imputation analysis using the 1,000 Genomes Project data combined with a functional prediction analysis revealed the presence of biologically relevant variants that correlate with the observed association signals. While the findings generated here warrant independent validation, the results of our large study suggest that ATM may be a novel locus associated with the risk of multiple subtypes of NHL.
PMCID:4092067
PMID: 25010664
ISSN: 1932-6203
CID: 1074882
Copy number alteration burden predicts prostate cancer relapse
Hieronymus, Haley; Schultz, Nikolaus; Gopalan, Anuradha; Carver, Brett S; Chang, Matthew T; Xiao, Yonghong; Heguy, Adriana; Huberman, Kety; Bernstein, Melanie; Assel, Melissa; Murali, Rajmohan; Vickers, Andrew; Scardino, Peter T; Sander, Chris; Reuter, Victor; Taylor, Barry S; Sawyers, Charles L
Primary prostate cancer is the most common malignancy in men but has highly variable outcomes, highlighting the need for biomarkers to determine which patients can be managed conservatively. Few large prostate oncogenome resources currently exist that combine the molecular and clinical outcome data necessary to discover prognostic biomarkers. Previously, we found an association between relapse and the pattern of DNA copy number alteration (CNA) in 168 primary tumors, raising the possibility of CNA as a prognostic biomarker. Here we examine this question by profiling an additional 104 primary prostate cancers and updating the initial 168 patient cohort with long-term clinical outcome. We find that CNA burden across the genome, defined as the percentage of the tumor genome affected by CNA, was associated with biochemical recurrence and metastasis after surgery in these two cohorts, independent of the prostate-specific antigen biomarker or Gleason grade, a major existing histopathological prognostic variable in prostate cancer. Moreover, CNA burden was associated with biochemical recurrence in intermediate-risk Gleason 7 prostate cancers, independent of prostate-specific antigen or nomogram score. We further demonstrate that CNA burden can be measured in diagnostic needle biopsies using low-input whole-genome sequencing, setting the stage for studies of prognostic impact in conservatively treated cohorts.
PMCID:4121784
PMID: 25024180
ISSN: 0027-8424
CID: 1075112